Top-News

Kyverna Therapeutics Aktie News

Aktie
WKN:  A402W6 ISIN:  US5019761049 US-Symbol:  KYTX Branche:  Biotechnologie Land:  USA
7,80 $
-0,04 $
-0,51%
6,6988 € 21:59:57 Uhr
Depot/Watchlist
Marktkapitalisierung *
242,25 Mio. €
Streubesitz
24,62%
KGV
-1,27
Index-Zuordnung
-

Kyverna Therapeutics News

29.07.25 - PR Newswire
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise PR Newswire
28.05.25 - PR Newswire
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference PR Newswire
13.05.25 - PR Newswire
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results PR Newswire
27.03.25 - PR Newswire
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
03.03.25 - PR Newswire
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference PR Newswire
07.02.25 - PR Newswire
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit PR Newswire
07.02.25 - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics PR Newswire
07.02.25 - PR Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ...
06.02.25 - PR Newswire
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX PR Newswire
04.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Kyverna Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - KYTX ...
04.02.25 - PR Newswire
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
04.02.25 - PR Newswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm PR Newswire
04.02.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX PR Newswire
03.02.25 - PR Newswire
The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX
The Gross Law Firm Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX PR Newswire
01.02.25 - PR Newswire
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit PR Newswire
31.01.25 - PR Newswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS ...
31.01.25 - PR Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of ...
30.01.25 - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics PR Newswire
30.01.25 - PR Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights - KYTX PR Newswire
29.01.25 - PR Newswire
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Kyverna Therapeutics, Inc. (KYTX) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »